This Plain Language Summary of Publication article (PLSP) from Future Rare Diseases covers focal segmental glomerulosclerosis (FSGS), a kidney scarring condition that causes protein leakage into urine (proteinuria) and can progress to kidney failure. The DUET and DUPLEX studies evaluated sparsentan’s effectiveness in lowering proteinuria and its safety profile in FSGS patients.

Visit the site using this link to read the article.

This PLSP is based on three articles called ‘DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS’ and was published in the Journal of the American Society of Nephrology.

‘Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial’ and was published in Kidney International Reports.

‘Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis’ and was published in The New England Journal of Medicine. 

Visit JASN using the link to read the original article.

Visit ISN using the link to read the original article.

Visit NEJM using the link to read the original article.